原发性巨球蛋白血症(waldenstrom-macroglobulinemia, WM)是一种惰性的非霍奇金淋巴瘤,发病率较低,在非霍奇金淋巴瘤患者中大约仅1%~2%,WM大多数患者都含有MYD88突变,本文介绍1例MYD88突变阴性患者的诊断治疗过程并文献复习。
Waldenstrom-macroglobulinemia (WM) is an inert non Hodgkin’s lymphoma with a low incidence rate, which is only about 1%~2% in patients with non Hodgkin’s lymphoma. Most patients with WM contain MYD88 mutations. This paper introduces the diagnosis and treatment of a patient with negative MYD88 mutation and reviews the literature.
Waldenstrom-macroglobulinemia (WM) is an inert non Hodgkin’s lymphoma with a low incidence rate, which is only about 1%~2% in patients with non Hodgkin’s lymphoma. Most patients with WM contain MYD88 mutations. This paper introduces the diagnosis and treatment of a patient with negative MYD88 mutation and reviews the literature.
李 帅,吕世玉,王丽娟. MYD88突变阴性的原发性巨球蛋白血症1例A Case of MYD88 Mutation Negative Waldenstrom-Macroglobulinemia[J]. 临床医学进展, 2022, 12(10): 8928-8932. https://doi.org/10.12677/ACM.2022.12101290
参考文献ReferencesCampo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. and Jaffe, E.S. (2011) The 2008 WHO Classification of Lymphoid Neoplasms and Beyond: Evolving Concepts and Practical Applications. Blood, 117, 5019-5032.
<br>https://doi.org/10.1182/blood-2011-01-293050Kasi, P.M., Ansell, S.M. and Gertz, M.A. (2015) Walden-ström macroglobulinemia. Clinical Advances in Hematology & Oncology: H&O, 13, 56-66.Fonseca, R. and Hay-man, S. (2007) Waldenström macroglobulinaemia. British Journal of Haematology, 138, 700-720.
<br>https://doi.org/10.1111/j.1365-2141.2007.06724.xTreon, S.P., Gertz, M.A., Dimopoulos, M., Anagnos-topoulos, A., Blade, J., Branagan, A.R., et al. (2006) Update on Treatment Recommendations from the Third Internation-al Workshop on Waldenstrom’s Macroglobulinemia. Blood, 107, 3442-3446. <br>https://doi.org/10.1182/blood-2005-02-0833Sekhar, J., Sanfilippo, K., Zhang, Q., Trinkaus, K., Vij, R. and Morgensztern, D. (2012) Waldenstrom Macroglobulinemia: A Surveillance, Epidemiology, and End Results Database Review from 1988 to 2005. Leukemia & Lymphoma, 53, 1625-1626. <br>https://doi.org/10.3109/10428194.2012.656103Treon, S.P., Cao, Y., Xu, L., Yang, G., Liu, X. and Hunter, Z.R. (2014) Somatic Mutations in MYD88 and CXCR4 Are Determinants of Clinical Presentation and Overall Survival in Waldenstrom Macroglobulinemia. Blood, 123, 2791-2796. <br>https://doi.org/10.1182/blood-2014-01-550905Treon, S.P., Gustine, J., Xu, L., Manning, R.J., Tsakmaklis, N., Demos, M., et al. (2018) MYD88 Wild-Type Waldenstrom Macroglobulinaemia: Differential Diagnosis, Risk of Histological Transformation, and Overall Survival. British Journal of Haematology, 180, 374-380. <br>https://doi.org/10.1111/bjh.15049Spinner, M.A., Varma, G. and Advani, R.H. (2018) Novel Approaches in Waldenstrom Macroglobulinemia. Hematology/Oncology Clinics of North America, 32, 875-890. <br>https://doi.org/10.1016/j.hoc.2018.05.014Treon, S.P., Xu, L., Guerrera, M.L., Jimenez, C., Hunter, Z.R., Liu, X., et al. (2020) Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. Jour-nal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38, 1198-1208. <br>https://doi.org/10.1200/JCO.19.02314Abeykoon, J.P., Paludo, J., King, R.L., Ansell, S.M., Gertz, M.A., LaPlant, B.R., et al. (2018) MYD88 Mutation Status Does Not Impact Overall Survival in Waldenstrom Macroglobu-linemia. American Journal of Hematology, 93, 187-194.
<br>https://doi.org/10.1002/ajh.24955Zanwar, S., Abeykoon, J.P., Durot, E., King, R., Perez Burbano, G.E., Ku-mar, S., et al. (2020) Impact of MYD88 (L265P) Mutation Status on Histological Transformation of Waldenstrom Mac-roglobulinemia. American Journal of Hematology, 95, 274-281. <br>https://doi.org/10.1002/ajh.25697Ghobrial, I.M., Fonseca, R., Gertz, M.A., Plevak, M.F., Larson, D.R., Therneau, T.M., et al. (2006) Prognostic Model for Dis-ease-Specific and Overall Mortality in Newly Diagnosed Symptomatic Patients with Waldenstrom Macroglobulinaemia. British Journal of Haematology, 133, 158-164.
<br>https://doi.org/10.1111/j.1365-2141.2006.06003.xBenevolo, G., Nicolosi, M., Santambrogio, E. and Vitolo, U. (2017) Current Options to Manage Waldenstrom’s Macroglobulinemia. Expert Review of Hematology, 10, 637-647. <br>https://doi.org/10.1080/17474086.2017.1339596Buske, C., Hoster, E., Dreyling, M., Eimermacher, H., Wandt, H., Metzner, B., et al. (2009) The Addition of Rituximab to Front-Line Therapy with CHOP (R-CHOP) Results in a Higher Response Rate and Longer Time to Treatment Failure in Patients with Lymphoplasmacytic Lymphoma: Re-sults of a Randomized Trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia, 23, 153-161. <br>https://doi.org/10.1038/leu.2008.261Treon, S.P., Tripsas, C.K., Meid, K., Kanan, S., Sheehy, P., Chuma, S., et al. (2014) Carfilzomib, Rituximab, and Dexamethasone (CaRD) Treatment Offers a Neuropathy-Sparing Approach for Treating Waldenstrom’s Macroglobulinemia. Blood, 124, 503-510. <br>https://doi.org/10.1182/blood-2014-03-566273Dimopoulos, M.A., Tedeschi, A., Trotman, J., Garcia-Sanz, R., Macdonald, D., Leblond, V., et al. (2018) Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom’s Macroglobuline-mia. The New England Journal of Medicine, 378, 2399-2410. <br>https://doi.org/10.1056/NEJMoa1802917Grimont, C.N., Castillo Almeida, N.E. and Gertz, M.A. (2021) Current and Emerging Treatments for Waldenstrom Macroglobulinemia. Acta Haematologica, 144, 146-157. <br>https://doi.org/10.1159/000509286